AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: Protection from an intraclade challenge administered systemically or mucosally by an attenuated vaccine

Journal of Virology

Volumn 77, Issue 20, 2003, Pages 10740-10750

  Pistello, Mauro ^a   Matteucci, Donatella ^a   Bonci, Francesca ^a   Isola, Patrizia ^a   Mazzetti, Paola ^a   Zaccaro, Lucia ^a   Merico, Antonio ^a   Del Mauro, Daniela ^a   Flynn, Norman ^b   Bendinelli, Mauro ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LIVE VACCINE; VIRUS DNA; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CAT; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FELINE IMMUNODEFICIENCY VIRUS; FEMALE; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; T LYMPHOCYTE; VIRUS INFECTION; VIRUS REPLICATION;

AIDS VACCINES; ANIMALS; BASE SEQUENCE; CATS; DISEASE MODELS, ANIMAL; FELINE ACQUIRED IMMUNODEFICIENCY SYNDROME; FEMALE; IMMUNODEFICIENCY VIRUS, FELINE; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; VACCINATION; VACCINES, ATTENUATED; VIRAL VACCINES;

EID: 0141454830     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.77.20.10740-10750.2003     Document Type: Article

References (75)

1. Abel, K., L. Compton, T. Rourke, D. Montefiori, D. Lu, K. Rothaeusler, L. Fritts, K. Bost, and C. J. Miller. 2003. Simian-human immunodeficiency virus SHIV89.6-induced protection against intravaginal challenge with pathogenic SIVmac239 is independent of the roule of immunization and is associated with a combination of cytotoxic T lymphocytes and alpha interferon responses. J. Virol. 77:3099-3118.
2. Almond, N., and J. Stott. 1999. Live attenuated SIV-a model of a vaccine for AIDS. Immunol. Lett. 66:167-170.
3. Altfeld, M., T. M. Allen, X. G. Yu, M. N. Johnston, D. Agrawal, B. T. Korber, D. C. Montefiori, D. H. O'Connor, B. T. Davis, P. K. Lee, E. L. Maier, J. Harlow, P. J. Goulder, C. Brander, E. S. Rosenberg, and B. D. Walker. 2002. HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus. Nature 420:434-439.
4. Bachmann, M. H., D. L. Sodora, M. Matthiason-Dubard, G. H. Learn, A. G. Rodrigo, P. Mazzetti, E. A. Hoover, and J. I. Mullins. 1997. Genetic diversity of feline immunodeficiency virus: dual infection, recombination and distinct evolutionary rates between envelope sequence clades. J. Virol. 71:4241-4253.
5. Badgett, M. R., A. Auer, L. E. Carmichael, C. R. Parrish, and J. J. Bull. 2002. Evolutionary dynamics of viral attenuation. J. Virol. 76:10524-10529.
6. Barlough, J. E., T. W. North, C. L. Oxford, K. M. Remington, S. Dandekar, M. N. Ellis, and N. C. Pedersen. 1993. Feline immunodeficiency virus infection of cats as a model to test the effect of certain selection pressures on the infectivity and virulence of resultant lentivirus variants. Antivir. Res. 22:259-272.
7. Bendinelli, M., M. Pistello, D. Del Mauro, G. Cammarota, F. Maggi, A. Leonildi, S. Giannecchini, C. Bergamini, and D. Matteucci. 2001. During readaptation in vivo, a tissue culture-adapted strain of feline immunodeficiency virus reverts to broad neutralization resistance at different times in individual hosts but through changes at the same position of the surface glycoprotein. J. Virol. 75:4584-4593.
8. Berkhout, B., K. Verhoef, G. Marzio, B. Klaver, M. Vink, X. Zhou, and A. T. Das. 2002. Conditional virus replication as an approach to a safe live attenuated human immunodeficiency virus vaccine. J. lqeurovirol. 8:134-137.
9. Bishop, S. A., C. R. Stokes, T. J. Gruffydd-Jones, C. V. Whiting, J. E. Humphries, R. Osborne, M. Papanastasopoulou, and D. A. Harbour. 1996. Vaccination with fixed feline immunodeficiency virus (FIV) infected cells: protection, breakthrough and specificity of response. Vaccine 14:1243-1250.
10. Blackard, J. T., D. E. Cohen, and K. H. Mayer. 2002. Human immunodeficiency virus superinfection and recombination: current state of knowledge and potential clinical consequences. Clin. Infect. Dis. 34:1108-1114.
11. Blower, S. M., K. Koelle, D. E. Kirschner, and J. Mills. 2001. Live attenuated HIV vaccines: predicting the tradeoff between efficacy and safety. Proc. Natl. Acad. Sci. USA 98:3618-3623.
12. Burkhard, M. J., L. A. Obert, L. L. O'Neil, L. J. Diehl, and E. A. Hoover. 1997. Mucosal transmission of cell-associated and cell-free feline immunodeficiency virus. AIDS Res. Hum. Retrovir. 13:347-355.
13. Burkhard, M. J., C. K. Mathiason, K. O'Halloran, and E. A. Hoover. 2002. Kinetics of early FIV infection in cats exposed via the vaginal versus intravenous route. AIDS Res. Hum. Retrovir. 18:217-226.
14. Butterworth, J. L., R. V. English, H. L. Jordan, and M. B. Tompkins. 2001. Distribution of immune cells in the female reproductive tract in uninfected and FIV infected cats. Vet. Immunol. Immunopathol. 83:37-51.
15. Connor, R., D. Montefiori, J. Binley, J. Moore, S. Bonhoeffer, A. Gettie, E. Fenamore, K. Sheridan, D. Ho, P. Dailey, and P. Marx. 1998. Temporal analyses of virus replication, immune responses, and efficacy in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine. J. Virol. 72:7501-7509.
16. Cranage, M. P., A. M. Whatmore, S. A. Sharpe, N. Cook, N. Polyanskaya, S. Leech, J. D. Smith, E. W. Rud, M. J. Dennis, and G. A. Hall. 1997. Macaques infected with live attenuated SIVmac are protected against superinfection via the rectal mucosa. Virology 229:143-154.
17. Daniel, M. D., F. Kirchhoff, S. C. Czajak, P. K. Sehgal, and R. C. Desrosiers. 1992. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 258:1938-1941.
18. Del Mauro, D., D. Matteucci, S. Giannecchini, F. Maggi, M. Pistello, and M. Bendinelli. 1998. Autologous and heterologous neutralization analyses of primary feline immunodeficiency virus isolates. J. Virol. 72:2199-2207.
19. Denesvre, C., R. Le Grand, F. Boissin-Cans, L. Chakrabarti, B. Hurtrel, B. Vaslin, D. Dormont, and P. Sonigo. 1995. Highly attenuated SIVmac142 is immunogenic but does not protect against SIVmac251 challenge. AIDS Res. Hum. Retrovir. 11:1397-1406.
20. Desrosiers, R. C., J. D. Lifson, J. S. Gibbs, S. C. Czajak, A. Y. Howe, L. O. Arthur, and R. P. Johnson. 1998. Identification of highly attenuated mutants of simian immunodeficiency virus. J. Virol. 72:1431-1437.
21. Elder, J. H., G. A. Dean, E. A. Hoover, J. A. Hoxie, M. H. Malim, L. Mathes, J. C. Neil, T. W. North, E. E. Sparger, M. B. Tompkins, W. A. Tompkins, J. Yamamoto, N. Yuhki, N. C. Pedersen, and R. H. Miller. 1998. Lessons from the cat: feline immunodeficiency virus as a tool to develop intervention strategies against human immunodeficiency virus type 1. AIDS Res. Hum. Retrovir. 14:797-801.
22. Enose, Y., M. Ui, A. Miyake, H. Suzuki, H. Uesaka, T. Kuwata, J. Kunisawa, H. Kiyono, H. Takahashi, T. Miura, and M. Hayami. 2002. Protection by intranasal immunization of a nef-deleted, nonpathogenic SHIV against intravaginal challenge with a heterologous pathogenic SHIV. Virology 298:306-316.
23. Finerty, S., C. R. Stokes, T. J. Gruffydd-Jones, T. J. Hillman, N. A. Reeves, C. V. Whiting, W. M. Schaaper, K. Dalsgaard, and D. A. Harbour. 2000. Mucosal immunization with experimental feline immunodeficiency virus (FIV) vaccines induces both antibody and T cell responses but does not protect against rectal FIV challenge. Vaccine 18:3254-3265.
24. Finerty, S., C. R. Stokes, T. J. Gruffydd-Jones, T. J. Hillman, F. J. Barr, and D. A. Harbour. 2001. Targeted lymph node immunization can protect cats from a mucosal challenge with feline immunodeficiency virus. Vaccine 20:49-58.
25. Fultz, P. N., Q. Wei, and L. Yue. 1999. Rectal transmission of human immunodeficiency virus type 1 to chimpanzees. J. Infect. Dis. 179:418-421.
26. Goto, Y., Y. Nishimura, K. Baba, T. Mizuno, Y. Endo, K. Masuda, K, Ohno, and H. Tsujimoto. 2002. Association of plasma viral RNA load with prognosis in cats naturally infected with feline immunodeficiency virus. J. Virol. 76:10079-10083.
27. Goulder, P. J. R., and B. D. Walker. 2002. HIV-1 superinfection-a word of caution. N. Engl. J. Med. 347:756-758.
28. Gupta, P., K. B. Collins, D. Ratner, S. Watkins, G. J. Naus, D. V. Landers, and B. K. Patterson. 2002. Memory CD4(+) T cells are the earliest detectable human immunodeficiency virus type 1 (HIV-1)-infected cells in the female genital mucosal tissue during HIV-1 transmission in an organ culture system. J. Virol. 76:9868-9876.
29. Hosie, M. J., J. N. Flynn, M. A. Rigby, C. Cannon, T. Dunsford, N. A. Mackay, D. Argyle, B. J. Willett, T. Miyazawa, D. E. Onions, O. Jarrett, and J. C. Neil. 1998. DNA vaccination affords significant protection against feline immunodeficiency virus infection without inducing detectable antiviral antibodies. J. Virol. 72:7310-7319.
30. Hosie, M. J., T. Dunsford, D. Klein, B. J. Willett, C. Cannon, R. Osborne, J. MacDonald, N. Spibey, N. Mackay, O. Jarrett, and J. C. Neil. 2000. Vaccination with inactivated virus but not viral DNA reduces virus load following challenge with a heterologous and virulent isolate of feline immunodeficiency virus. J. Virol. 74:9403-9411.
31. Hosie, M. J., B. J. Willett, D. Klein, T. H. Dunsford, C. Cannon, M. Shimojima, J. C. Neil, and O. Jarrett. 2002. Evolution of replication efficiency following infection with a molecularly cloned feline immunodeficiency virus of low virulence. J. Virol. 76:6062-6072.
32. Ignatius, R., K. Tenner-Racz, D. Messmer, A. Gettie, J. Blanchard, A. Luckay, C. Russo, S. Smith, P. A. Marx, R. M. Steinman, P. Racz, and M. Pope. 2002. Increased macrophage infection upon subcutaneous inoculation of rhesus macaques with simian immunodeficiency virus-loaded dendritic cells or T cells but not with cell-free virus. J. Virol. 76:9787-9797.
33. Johnson, R. P. 2002. Mechanisms of protection against simian immunodeficiency virus infection. Vaccine 20:1985-1987.
34. Johnson, R. P., and R. C. Desrosiers. 1998. Protective immunity induced by live attenuated simian immunodeficiency virus. Curr. Opin. Immunol. 10:436-443.
35. Johnson, R. P., J. D. Lifson, S. C. Czajak, K. S. Cole, K. H. Manson, R. Glickman, J. Yang, D. C. Montefiori, R. Montelaro, M. S. Wyand, and R. C. Desrosiers. 1999. Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation. J. Virol. 73:4952-4961.
36. Jost, S., M. C. Bernard, L. Kaiser, S. Yerly, B. Hirschel, A. Samri, B. Autran, L. E. Goh, and L. Perrin. 2002. A patient with HIV-1 superinfection. N. Engl. J. Med. 347:731-736.
37. Kahn, P. 2002. Superinfection: what does it mean for vaccines? IAVI Rep. 4:3-4.
38. Kent, S. J., C. J. Dale, S. Preiss, J. Mills, D. Campagna, and D. F. J. Purcell. 2001. Vaccination with attenuated simian immunodeficiency virus by DNA inoculation. J. Virol. 75:11930-11934.
39. Khatissian, E., V. Monceaux, M.-C. Cumont, M.-P. Kieny, A.-M. Aubertin, and B. Hurtrel. 2001. Persistence of pathogenic challenge virus in macaques protected by simian immunodeficiency virus SIVmacΔnef, J. Virol. 75:1507-1515.
40. Kumar, A., S. Mukherjee, J. Shen, S. Buch, Z. Li, I. Adany, Z. Liu, W. Zhuge, M. Piatak, Jr., J. Lifson, H. McClure, and O. Narayan. 2002. Immunization of macaques with live simian human immunodeficiency virus (SHIV) vaccines conferred protection against AIDS induced by homologous and heterologous SHIVs and simian immunodeficiency virus. Virology 301:189-205.
41. Letvin, N. J., D. H. Barouch, and D. C. Montefiori. 2002. Prospects for vaccine protection against HIV-1 infection and AIDS. Annu. Rev. Immunol. 20:73-99.
42. Leutenegger, C. M., D. Klein, R. Hofman-Lehmann, C. Mislin, U. Hummel, J. Boni, F. Boretti, W. H. Guenzburg, and H. Lutz. 1999. Rapid feline immunodeficiency virus provirus quantitation by polymerase chain reaction using the TaqMan fluorogenic real-time detection system. J. Virol. Methods 78:105-116.
43. Liu, S.-L., J. E. Mittler, D. C. Nickle, T. M. Mulvania, D. Shriner, A. G. Rodrigo, B. Kosloff, X. He, L. Corey, and J. I. Mullins. 2002. Selection for human immunodeficiency virus type 1 recombinants in a patient with rapid progression to AIDS. J. Virol. 76:10674-10684.
44. Lockridge, K. M., M. Chien, G. A. Dean, K. Stefano Cole, R. C. Montelaro, P. A. Luciw, and E. E. Sparger. 2000. Protective immunity against feline immunodeficiency virus induced by inoculation with vif-deleted proviral DNA. Virology 273:67-79.
45. Lohman, B. L., M. B. McChesney, C. J. Miller, E. McGowan, S. M. Joye, K. K. Van Rompay, E. Reay, L. Antipa, N. C. Pedersen, and M. L. Marthas. 1994. A partially attenuated simian immunodeficiency virus induces host immunity that correlates with resistance to pathogenic virus challenge. J. Virol. 68:7021-7029.
46. Macadam, A. J., G. Ferguson, D. M. Stone, J. Meredith, J. W. Almond, and P. D. Minor. 2001. Live-attenuated strains of improved genetic stability. Dev. Biol. 105:179-187.
47. Matteucci, D., M. Pistello, P. Mazzetti, S. Giannecchini, D. Del Mauro, I. Lonetti, L. Zaccaro, C. Pollera, S. Specter, and M. Bendinelli. 1997. Studies of AIDS vaccination using an ex vivo feline immunodeficiency virus model: protection conferred by a fixed-cell vaccine against cell-free and cell-associated challenge differs in duration and is not easily boosted. J. Virol. 71:8368-8376.
48. Matteucci, D., M. Pistello, P. Mazzetti, S. Giannecchini, P. Isola, A. Merico, A. Rizzuto, and M. Bendinelli. 2000. AIDS vaccination studies using feline immunodeficiency virus as a model: immunisation with inactivated whole virus suppresses viral replication following intravaginal challenge with infected cats. Vaccine 18:119-130.
49. Matteucci, D., A. Poli, P. Mazzetti, S. Sozzi, F. Bonci, P. Isola, L. Zaccaro, S. Giannecchini, M. Calandrella, M. Pistello, S. Specter, and M. Bendinelli. 2000. Immunogenicity of an anti-clade B feline immunodeficiency fixed-cell virus vaccine in field cats. J. Virol. 74:10911-10919.
50. Miller, C. J., M. B. McChesney, X. Lü, P. J. Dailey, C. Chutkowski, D. Lu, P. Brosio, B. Roberts, and Y. Lu. 1997. Rhesus macaques previously infected with simian/human immunodeficiency virus are protected from vaginal challenge with pathogenic SIVmac239. J. Virol. 71:1911-1921.
51. Mills, J., R. Desrosiers, E. Rud, and N. Almond. 2000. Live attenuated HIV vaccines: a proposal for further research and development. AIDS Res. Hum. Retrovir. 16:1453-1461.
52. Mooij, P., W. M. J. M. Bogers, H. Oostermeijer, W. Koornstra, P. J. F. Ten Haaft, B. E. Verstrepen, G. Van Der Auwera, and J. L. Heeney. 2000. Evidence for viral virulence as a predominant factor limiting human immunodeficiency virus vaccine efficacy. J. Virol. 74:4017-4027.
53. Mori, K., Y. Yasutomi, S. Ohgimoto, T. Nakasone, S. Takamura, T. Shioda, and Y. Nagai. 2001. Quintuple deglycosylation mutant of simian immunodeficiency virus SIVmac239 in rhesus macaques: robust primary replication, tightly contained chronic infection, and elicitation of potent immunity against the parental wild-type strain. J. Virol. 75:4023-4028.
54. Nabel, G. J. 2002. HIV vaccine strategies. Vaccine 20:1945-1947.
55. Nilsson, C., B. Makitalo, R. Thorstensson, S. Norley, D. Binninger-Schinzel, M. Cranage, E. Rud, G. Biberfeld, and P. Putkonen. 1998. Live attenuated simian immunodeficiency virus (SIV)mac in macaques can induce protection against mucosal infection with SIVsm. AIDS 12:2261-2270.
56. Norley, S., B. Beer, D. Binninger-Schinzel, T. Vogel, O. Hohn, E. Seibold, D. Radke, C. Cosma, and R. Kurth. 2002. Vaccine development using the simian immunodeficiency virus model for AIDS. Intervirology 45:267-274.
57. Obert, L. A., and E. A. Hoover. 2002. Early pathogenesis of transmucosal feline immunodeficiency virus infection. J. Virol. 76:6311-6322.
58. Pedersen, N. C., J. K. Yamamoto, T. Ishida, and H. Hansen. 1989. Feline immunodeficiency virus infection. Vet. Immunol. Immunopathol. 21:111-129.
59. Pistello, M., D. Matteucci, G. Cammarota, P. Mazzetti, S. Giannecchini, D. Del Mauro, S. Macchi, L. Zaccaro, and M. Bendinelli. 1999. Kinetics of preinfecting and challenge virus replication during a three-year interclade feline immunodeficiency virus superinfection experiment in cats. J. Virol. 73:1518-1527.
60. Pistello, M., M. Moscardini, P. Mazzetti, S. Macchi, F. Bonci, P. Isola, G. Freer, D. Matteucci, S. Specter, and M. Bendinelli. 2002. Development of feline immunodeficiency virus ORF-A (tat) mutants: in vitro and in vivo characterization. Virology 298:84-95.
61. Quesada-Rolander, M., B. Makitalo, R. Thorstensson, Y. J. Zhang, E. Castanos-Velez, G. Biberfeld, and P. Putkonen. 1996. Protection against mucosal SIVsm challenge in macaques infected with a chimeric SIV that expresses HIV type 1 envelope. AIDS Res. Hum. Retrovir. 12:993-999.
62. Ramos, A., D. J. Hu, L. Nguyen, K.-O. Phan, S. Vanichseni, N. Promadej, K. Choopanya, M. Callahan, N. L. Young, J. McNicholl, T. D. Mastro, T. M. Folks, and S. Subbarao. 2002. Intersubtype human immunodeficiency virus type 1 superinfection following seroconversion to primary infection in two injection drug users. J. Virol. 76:7444-7452.
63. Reed, L. J., and H. A. Muench. 1938. A simple method for estimating fifty percent end points. Am. J. Hyg. 27:493-497.
64. Robinson, H. L. 2002. New hope for an AIDS vaccine. Nat. Rev. Immunol. 2:239-250.
65. Shacklett, B. L., K. E. S. Shaw, L. A. Adamson, D. T. Wilkens, C. A. Cox, D. C. Montefiori, M. B. Gardner, P. Sonigo, and P. A. Luciw. 2002. Live, attenuated simian immunodeficiency virus SIVmac-M4, with point mutations in the env transmembrane protein intracytoplasmic domain, provides partial protection from mucosal challenge with pathogenic SIVmac251. J. Virol. 76:11363-11378.
66. Sodora, D. L., A. Gettie, C. J. Miller, and P. A. Marx. 1998. Vaginal transmission of SIV: assessing infectivity and hormonal influences in macaques inoculated with cell-free and cell-associated viral stocks. AIDS Res. Hum. Retrovir. 14:S119-S123.
67. Stebbings, R. J., N. M. Almond, E. J. Stott, N. Berry, A. M. Wade-Evans, R. Hull, J. Lines, P. Silvera, R. Sangster, T. Corcoran, J. Rose, and K. B. Walker. 2002. Mechanisms of protection induced by attenuated simian immunodeficiency virus. Virology 296:338-353.
68. Uhl, E. W., T. G. Heaton-Jones, R. Pu, and J. K. Yamamoto. 2002. FIV vaccine development and its importance to veterinary and human medicine: a review. FIV vaccine 2002 update and review. Vet. Immunol. Immunopathol. 90:113-132.
69. United Nations Program on HIV/AIDS-World Health Organization. 2002. AIDS epidemic update. December 2001. United Nations Program on HIV/ AIDS-World Health Organization, Geneva, Switzerland.
70. Van Rompay, K. K. A., J. L. Greenier, K. Stefano Cole, P. Earl, B. Moss, J. D. Steckbeck, B. Pahar, T. Rourke, R. C. Montelaro, D. R. Canfield, R. P. Tarara, C. Miller, M. B. McChesney, and M. L. Marthas. 2003. Immunization of newborn rhesus macaques with simian immunodeficiency virus (SIV) vaccines prolongs survival after oral challenge with virulent SIVmac251. J. Virol. 77:179-190.
71. Warren, J. 2002. Preclinical AIDS vaccine research: survey of SIV, SHIV, and HIV challenge studies in vaccinated nonhuman primates. J. Med. Primatol. 31:237-256.
72. Willett, B. J., M. J. Hosie, T. H. Dunsford, J. C. Neil, and O. Jarrett. 1991. Productive infection of T-helper lymphocytes with feline immunodeficiency virus is accompanied by reduced expression of CD4. AIDS 5:1469-1475.
73. Willett, B. J., J. N. Flynn, and M. J. Hosie. 1997. FIV infection of the domestic cat: an animal model for AIDS. Immunol. Today 18:182-189.
74. Wyand, M. S., K. Manson, D. C. Montefiori, J. D. Lifson, R. P. Johnson, and R. C. Desrosiers. 1999. Protection by live, attenuated simian immunodeficiency virus against heterologous challenge. J. Virol. 73:8356-8363.
75. Yamamoto, J. K., C. D. Ackley, H. Zochlinski, H. Louie, E. Pembroke, M. Torten, H. Hansen, R. Munn, and T. Okuda. 1991. Development of interleukin-2 independent feline lymphoid cell lines chronically infected with feline immunodeficiency virus: importance for diagnostic reagents and vaccines. Intervirology 32:361-375.